Welcome to our dedicated page for Healthwarehouse news (Ticker: HEWA), a resource for investors and traders seeking the latest updates and insights on Healthwarehouse stock.
Healthwarehouse (HEWA) operates as America's only verified internet pharmacy practice site, providing FDA-approved prescription medications and over-the-counter products through secure mail-order services. This page aggregates official company announcements, regulatory developments, and strategic initiatives essential for understanding its position in the online pharmacy sector.
Investors and healthcare professionals will find timely updates on earnings reports, compliance milestones, and partnership announcements. All content is curated to highlight HEWA's commitment to affordable healthcare delivery while maintaining strict adherence to state and federal pharmaceutical regulations.
Key coverage areas include new product launches, veterinary medication expansions, and operational updates from the company legally licensed to dispense medications in all 50 states. Regular visitors gain insights into how HEWA navigates complex pharmacy regulations while serving underinsured populations.
Bookmark this page for streamlined access to verified Healthwarehouse news. Check back frequently for objective reporting on prescription drug distribution innovations and regulatory achievements in the digital pharmacy space.
HealthWarehouse.com (OTCQB:HEWA) reported significant growth for the full year 2024, with net sales reaching $33.6 million, marking a 66% increase from 2023. The growth was primarily driven by a 78% increase in prescription revenues, reaching $30.9 million, though offset by a 6.3% decline in over-the-counter sales.
The company reported a net loss of $333,000 for the year, but achieved positive cash flow with Adjusted EBITDA of $1.1 million. The fourth quarter showed strong performance with net income of $189,000 and Adjusted EBITDA of $523,000.
While gross profit increased by 16% to $14.1 million, the gross margin percentage decreased from 60% to 42% due to lower margins in prescription sales. Operating expenses remained controlled, with SG&A expenses increasing only 3.1% despite the significant revenue growth.
HealthWarehouse.com (OTC:HEWA) reported record Q3 2024 results with net sales of $9.0 million, an 89% increase from Q3 2023. The company achieved net income of $74,000 and Adjusted EBITDA of $405,000. Prescription sales grew 96.3% to $8.3 million, driven by strong growth in GLP-1 weight loss medications. Gross profit increased to $3.8 million, though margins decreased to 42% due to price competition. The company also secured extension of convertible note maturity to 2026, strengthening its capital position.
HealthWarehouse.com (OTC:HEWA) reported Q2 2024 results with net sales of $5.8 million, a 9% increase from Q2 2023. The growth was driven by strong performance in partner services and B2C prescription revenue, particularly from GLP-1 weight loss medications. However, the company posted a net loss of $344,000 for Q2 and $596,000 for H1 2024. Prescription sales rose 12.8% to $5.1 million in Q2, while over-the-counter sales decreased 14.3% to $643,000. Gross profit declined due to lower margins, but operating expenses decreased by 10.1%. The company's Adjusted EBITDA broke even for Q2, improving from a $152,000 loss in Q2 2023.
HealthWarehouse.com, Inc. (HEWA) reported a 3% decrease in net sales totaling $5.1 million for the first quarter of 2024 compared to the same period in 2023. The company reported a net loss of $252,412 and positive EBITDA of $89,723 for the quarter. Despite the decline in revenue, HealthWarehouse.com experienced a 7% growth in direct-to-consumer prescription sales. The company remains optimistic about future sales growth in 2024, focusing on new partnerships and recovering lost sales due to supply issues. HealthWarehouse.com continues to invest in technology to enhance operational efficiency and customer experience. Gross profit decreased by 10.0% due to lower sales and margins. Operating expenses decreased by 8.8% primarily in advertising, marketing, shipping, and salaries, offset by increased expenses in software engineering and stock-based compensation. The company reported a net loss of $252,000 for the quarter, an improvement from the previous year, and an Adjusted EBITDA of $90,000.
HealthWarehouse.com, Inc. (OTCQB:HEWA) reported a 12% increase in net sales for 2022, totaling $18,142,633 driven by significant growth in partner services revenue. However, the company experienced a net loss of $952,029, worsening from $572,502 in 2021. Despite this, HealthWarehouse.com achieved positive cash flow for the sixth consecutive year with an Adjusted EBITDA of $146,787. Direct-to-consumer sales declined by 3.5%, while partner services revenue nearly doubled. Operating expenses rose by 10.7% to $12,725,433, largely due to increased shipping and salaries. The company plans to launch a new e-commerce platform in 2023.
HealthWarehouse.com, Inc. (OTC:HEWA) reported net sales of $4,681,302 for Q3 2022, an 11% increase from Q3 2021, driven by growth in partner services. The company recorded a loss from operations of $225,614, yet reported positive cash flow with an Adjusted EBITDA of $47,673. Prescription sales increased by 6.4% to $3,873,323, and OTC sales surged 46.2% to $736,265. Despite higher gross profit, operating expenses rose by 11.2%, leading to net losses slightly widening compared to last year. Future plans include launching a proprietary e-commerce platform aimed at improving customer retention.
